Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Sponsor
Asan Medical Center
Study ID
NCT00383812
Status
Unknown

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2. To assess the change in lesion characteristics of PCV * size of PCV * fluorescein leakage * foveal thickness 3. To investigate the safety of intravitreal Bevacizumab in patients with PCV 4. To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV

Key Dates

First listed
Oct 4, 2006
Start date
May 31, 2006
Status verified
Oct 2006
Completion
May 31, 2008

Study Design

Enrollment
20 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To assess the percentage of patients who gained an improvement in best corrected visual acuity (BCVA) by 15 letters of more.

Central Contacts

Related Studies